2005
DOI: 10.1158/1535-7163.mct-04-0077
|View full text |Cite
|
Sign up to set email alerts
|

Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines

Abstract: Bovine lactoferricin (LfcinB) is a cationic, amphipathic peptide that is cytotoxic for human and rodent cancer cells. However, the mechanism by which LfcinB causes the death of cancer cells is not well understood. Here, we show that in vitro treatment with LfcinB rapidly induced apoptosis in several different human leukemia and carcinoma cell lines as determined by DNA fragmentation assays and phosphatidylserine headgroup inversion detected by Annexin V binding to the surface of cancer cells. Importantly, Lfci… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
186
0
5

Year Published

2006
2006
2015
2015

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 234 publications
(197 citation statements)
references
References 58 publications
6
186
0
5
Order By: Relevance
“…44 LfcinB did not exhibit any cytotoxic activity against HUVECs, excluding the possibility that LfcinB simply caused HUVECs to undergo apoptosis, as occurs when various cancer cell lines are exposed to LfcinB. 24,27 Because both bovine lactoferrin and LfcinB are known to bind heparin, 29,30 our findings led us to hypothesize that LfcinB competed with bFGF and VEGF 165 for heparin-like binding sites on heparan sulfate proteoglycans on the surface of HUVECs. Heparan sulfate proteoglycans are required for bFGF and VEGF 165 binding and signaling through their respective cell-surface receptors.…”
Section: Discussionmentioning
confidence: 82%
See 3 more Smart Citations
“…44 LfcinB did not exhibit any cytotoxic activity against HUVECs, excluding the possibility that LfcinB simply caused HUVECs to undergo apoptosis, as occurs when various cancer cell lines are exposed to LfcinB. 24,27 Because both bovine lactoferrin and LfcinB are known to bind heparin, 29,30 our findings led us to hypothesize that LfcinB competed with bFGF and VEGF 165 for heparin-like binding sites on heparan sulfate proteoglycans on the surface of HUVECs. Heparan sulfate proteoglycans are required for bFGF and VEGF 165 binding and signaling through their respective cell-surface receptors.…”
Section: Discussionmentioning
confidence: 82%
“…Interestingly, glypican-1 is overexpressed by human breast and pancreatic cancer cells, 51,52 which might promote the binding of LfcinB to these tumor cell types. We therefore speculate that the selective cytotoxic activity that LfcinB exhibits against several different human breast carcinoma cell lines 27 may be, at least in part, attributable to interactions between LfcinB and cell-surface glypican-1.…”
Section: Discussionmentioning
confidence: 95%
See 2 more Smart Citations
“…Breast cancer in human is inhibited by several commercial BSA preparations during in vitro cell culture (Solak and Akin, 2012). Mader et al (2005) also demonstrated that the nature of both synthetic and pepsin-generated lactoferricin B is against human leukemia and carcinoma cell lines (Colon, breast and ovary). In an acidic environment, α-lactalbumin forms the HAMLET (human α-lactalbumin made lethal to tumor cells) complex with oleic acid which inhibits the proliferation of various tumors by an apoptosis like mechanism (Svensson et al, 2003).…”
Section: Anti-carcinogenic Activitymentioning
confidence: 93%